ABSTRACT
In recent years, the application of alpha particle-based nuclide targeted therapy in tumors has shown great potential. 225Ac is a nuclide that can be used for alpha radionuclide targeted therapy which has been studied at home and abroad. A number of preclinical and clinical trials have been carried out, and some achievements have been obtained. This article summarizes the current research status of several malignant tumors, and analyzes the challenges and progress faced by 225Ac in radionuclide targeted therapy.
ABSTRACT
Glioma is the most common central nervous system tumor, mainly derived from the interstitial cells of the nervous system, showing diffuse and infiltrative growth, with the characteristics of high morbidity, high postoperative recurrence, high mortality and low cure rate. Currently, radical resection followed by radiotherapy and chemotherapy is the first choice of treatment. Accurate delineation of GTV-T is of significance for precision radiotherapy after surgery. In addition, CT/MR fusion imaging has been commonly used in the delineation of tumor targets in glioma. In recent years, PET/MR has been more and more widely applied in tumors. In this article, the application and differences between PET/MR and CT/MR for target delineation in glioma were reviewed.